[go: up one dir, main page]

DE1100641B - Process for the preparation of basic substituted alkylxanthine derivatives - Google Patents

Process for the preparation of basic substituted alkylxanthine derivatives

Info

Publication number
DE1100641B
DE1100641B DEC15043A DEC0015043A DE1100641B DE 1100641 B DE1100641 B DE 1100641B DE C15043 A DEC15043 A DE C15043A DE C0015043 A DEC0015043 A DE C0015043A DE 1100641 B DE1100641 B DE 1100641B
Authority
DE
Germany
Prior art keywords
theobromine
ethyl
hydrochloride
derivatives
alkylxanthine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DEC15043A
Other languages
German (de)
Inventor
Dr Erwin Kohlstaedt
Dr Karl-Heinz Klingler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHEMIEWERK HOMBURG
ZWEIGNIEDERLASSUNG DER DEUTSCH
Evonik Operations GmbH
Original Assignee
CHEMIEWERK HOMBURG
ZWEIGNIEDERLASSUNG DER DEUTSCH
Deutsche Gold und Silber Scheideanstalt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DEC13727A priority Critical patent/DE1100640B/en
Priority to DEC13726A priority patent/DE1095285B/en
Priority claimed from DEC13726A external-priority patent/DE1095285B/en
Application filed by CHEMIEWERK HOMBURG, ZWEIGNIEDERLASSUNG DER DEUTSCH, Deutsche Gold und Silber Scheideanstalt filed Critical CHEMIEWERK HOMBURG
Priority to DEC15043A priority patent/DE1100641B/en
Priority claimed from DEC15044A external-priority patent/DE1100642B/en
Publication of DE1100641B publication Critical patent/DE1100641B/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/10Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

Verfahren zur Herstellung von basisch substituierten Alkylxanthinderivaten Zusatz zur Patentanmeldung C 13726 IV b/12 p (Auslegeschrift 1 095 285) Gegenstand des Patents der Patentanmeldung C 13726 IVb/12p ist ein Verfahren zur Herstellung von basisch substituierten Alkylxanthinderivaten durch Umsetzung von 1-bzw. 7-Halogenalkyl-3,7- bzw. -1, 3-dimethylxanthinen mit primären Oxyalkylaminen. Process for the preparation of basic substituted alkylxanthine derivatives Addition to patent application C 13726 IV b / 12 p (Auslegeschrift 1 095 285) subject of the patent of patent application C 13726 IVb / 12p is a method of manufacture of basic substituted alkylxanthine derivatives by reaction of 1 or. 7-haloalkyl-3,7- or -1, 3-dimethylxanthines with primary oxyalkylamines.

Die Erfindung ist demgegenüber dadurch gekennzeichnet, daß man hier 1-Halogenalkyl-3, 7-dimethylxanthine mit primären Alkyl-, Cycloalkyl-bzw. Aralkylaminen, zweckmäßig in Gegenwart von Lösungsmitteln, gegebenenfalls in einem geschlossenen Gefäß, bei höheren Temperaturen, vorzugsweise zwischen 110 und 170° C umsetzt. The invention is characterized in that here 1-haloalkyl-3, 7-dimethylxanthines with primary alkyl, cycloalkyl or. Aralkylamines, expediently in the presence of solvents, optionally in a closed Vessel, at higher temperatures, preferably between 110 and 170 ° C.

Bei diesen neuen sekundären Aminoverbindungen handelt es sich um gut wasserlösliche und neutrale Substanzen, die bei geringer Giftigkeit durch wertvolle pharmakologische Eigenschaften ausgezeichnet sind. Gegenüber den bereits bekannten entsprechenden tertiären Basen weisen sie z. B. folgende verbesserte therapeutische Eigenschaften auf : 1. Am isoliert schlagenden Froschherzen wurde bei einer Verdünnung von 1 : 100 000 folgende Erhöhung des Schlagvolumens gefunden : 1- (ß-Methylamino-äthyl)-theobrominhydrochlorid....................... 53% 1- (-ÄthyIamino-äthyl)-theobrominhydrochlorid..................... 8% 1- (-Propylamino-äthyl)-theobrominhydrochlorid....................... 20% 1- (j6-Isopropylamino-äthyl)-theobrominhydrochlorid...................... 15°/o 1-(ß-Cyclohexylamino-äthyl)-theobrominhydrochlorid....................... 20°/o l- (-Benzylamino-äthyl)-theobronünhydrochlorid....................... 24°/o Bei sämtlichen Derivaten außer 1-(ß-Isopropylaminoäthyl)-theobromin traten bei diesen Versuchen eine Verminderung der Restvolumina auf. Das bekannte 1-(ß-Diäthylamino-äthyl)-theobromin-hydrochlorid dagegen zeigte in derselben Versuchsanordnung eine Senkung des Schlagvolumens um 50 °/0 und eine Erhöhung des Restvolumes um 89%. These new secondary amino compounds are Easily water-soluble and neutral substances, with low toxicity due to valuable pharmacological properties are excellent. Compared to the already known corresponding tertiary bases they have z. B. the following improved therapeutic Properties on: 1. The isolated beating frog heart was diluted of 1: 100,000 the following increase in stroke volume was found: 1- (ß-methylamino-ethyl) -theobromine hydrochloride ....................... 53% 1- (-äthylamino-ethyl) -theobromine hydrochloride ..................... 8% 1- (-propylamino-ethyl) -theobromine hydrochloride ..... .................. 20% 1- (6-isopropylamino-ethyl) -theobromine hydrochloride ...................... 15% 1- (ß-Cyclohexylamino-ethyl) -theobromine hydrochloride ....................... 20% l- (-Benzylamino-ethyl) -theobronune hydrochloride ....................... 24 ° / o at all derivatives except 1- (ß-isopropylaminoethyl) -theobromine occurred with these Try to reduce the remaining volumes. The well-known 1- (ß-diethylamino-ethyl) -theobromine hydrochloride on the other hand, showed a decrease in stroke volume in the same experimental set-up 50 ° / 0 and an increase in the remaining volume by 89%.

2. Die koronarerweiternde Wirkung am Hund beträgtbei l- (j8-Äthylamino-äthyl)-theobromin-hydrochlorid ein Zehntel der Theophyllinwirkung, 1-(ß-Benzylamino-äthyl)-tehobromin-hydrochlorid ein Viertel der Theophyllinwirkung, l- (jS-Diäthylamino-äthyl)-theobromin-hydrochlorid ein Zwanzigstel der Theophyllinwirkung. 2. The coronary-dilating effect in dogs is 1- (8-ethylamino-ethyl) -theobromine hydrochloride one tenth of the theophylline effect, 1- (ß-benzylamino-ethyl) -tehobromine hydrochloride a quarter of the theophylline effect, l- (jS-diethylamino-ethyl) -theobromine hydrochloride one twentieth of the theophylline action.

3. Die diurethischen Wirkungen sind bei den sekundären Aminoverbindungen ähnlich wie die der tertiären Basen. Die Giftigkeiten sind jedoch wesentlich geringer. 3. The diurethic effects are with the secondary amino compounds similar to that of the tertiary bases. However, the toxicity is much lower.

Folgende LDSO-Werte wurden bei intraperitonealer Injektion bei der Maus gefunden : 1- (ß-Methylamino-äthyl)-theobrominhydrochlorid................... 1530 mg/kg 1- (ß-Äthylamino-äthyl)-theobrominhydrochlorid................... 1180 mg/kg 1- (ß-Propylamino-äthyl)-theobrominhydrochlorid................... 990 mg/kg 1-(ß-Isopropylamino-äthyl)-theobromin-hydrochlorid............... 1200 mg/kg 1- (ß-Diäthylamino-äthyl)-theobrominhydrochlorid................... 427 mg/kg Beispiel 1 1-(ß-Methylamino-äthyl)-theobromin-hydrochlorid 24,2 g 1-ß0-Chloräthyl-theobromin werden zusammen mit 400 ccm Methanol und 62 ccm 15%iger alkoholischer Methylaminlösung 4 Stunden im Autoklav auf 120 bis 130° C erhitzt. Die Reaktionslösung wird eingedampft, der Rückstand mit Aceton und Chloroform gewaschen und anschließend aus Methanol umkristallisiert. Man erhält so 17, 5g 1-(ß-Methylamino-äthyl)-theobromin-hydrochlorid vom Schmelzpunkt 272 bis 274° C.The following LDSO values were obtained with intraperitoneal injection in the Mouse found: 1- (ß-methylamino-ethyl) -theobromine hydrochloride ................... 1530 mg / kg 1- (ß-ethylamino-ethyl) -theobromine hydrochloride ................... 1180 mg / kg 1- (ß-propylamino-ethyl) -theobromine hydrochloride ................... 990 mg / kg 1- (ß-Isopropylamino-ethyl) -theobromine hydrochloride ............... 1200 mg / kg 1- (ß-diethylamino-ethyl) -theobromine hydrochloride ................... 427 mg / kg example 1 1- (ß-methylamino-ethyl) -theobromine hydrochloride 24.2 g 1-ß0-chloroethyl-theobromine together with 400 cc of methanol and 62 cc of 15% alcoholic methylamine solution Heated to 120 to 130 ° C in an autoclave for 4 hours. The reaction solution is evaporated, the residue washed with acetone and chloroform and then from methanol recrystallized. This gives 17.5 g of 1- (β-methylamino-ethyl) -theobromine hydrochloride from melting point 272 to 274 ° C.

Beispiel 2. Example 2.

1- (-Äthylamino-äthyl)-theobromin-hydrochlorid 50 g. 1-ß-Chloräthyl-theobromin, 76 ccm 37°JOige alkoholische Athylaminlösung und 500 ccm Methanol werden im Autoklav 4 Stunden bei 125 bis 130°C geschüttelt. 1- (-Ethylamino-ethyl) -theobromine hydrochloride 50 g. 1-ß-chloroethyl-theobromine, 76 ccm 37 ° JOige alcoholic ethylamine solution and 500 ccm methanol are in the autoclave Shaken for 4 hours at 125 to 130 ° C.

Nach Abdestillieren des Lösungsmittels wird der Rückstand mehrmaIs mit absolutem Alkohol ausgekocht. Man erhalt so 46 g l- (ß-Äthylamino-äthyl)-theobromin-hydrochlorid vom Schmelzpunkt 286 bis 289° C.After the solvent has been distilled off, the residue becomes several times boiled with absolute alcohol. This gives 46 g of l- (ß-ethylamino-ethyl) -theobromine hydrochloride from melting point 286 to 289 ° C.

Beispiel 3 l-ß-Chloräthyl-theobromin, 36 g n-Propylamin und 400 ccm Methanol werden in einem Stahlautoklav 3 Stunden lang bei 125 bis 135°C geschüttelt. Man erhält 43, 8 g 1-(ß-n-Propylamino-äthyl)-theobromin-hydrochlorid vom Schmelzpunkt 218° C. Example 3 l-ß-chloroethyl-theobromine, 36 g of n-propylamine and 400 cc Methanol are shaken in a steel autoclave for 3 hours at 125 to 135 ° C. 43.8 g of 1- (β-n-propylamino-ethyl) -theobromine hydrochloride with a melting point are obtained 218 ° C.

Beispiel 4 1- (-Isopropylamino-äthyl)-theobromin-hydrochlorid Aus 48, 4 g 1-ß-Chloräthyl-theobromin und 36 g Isopropylamin werden, analog wie im Beispiel 3 beschrieben, 28 g 1-(ß-Isoprypylamino-äthyl)-theobromin-hydrochlorid vom Schmelzpunkt 241 bis 244° C erhalten. Example 4 1- (-Isopropylamino-ethyl) -theobromine-hydrochloride Aus 48.4 g of 1-ß-chloroethyl-theobromine and 36 g of isopropylamine are analogous to the example 3 described, 28 g of 1- (ß-isoprypylamino-ethyl) -theobromine hydrochloride of the melting point 241 to 244 ° C.

Beispiel 5 1-(ß-cyclohexylamino-äthyl)-theolbromin-hydrochlorid 41, 5 g l-ß-Chloräthyl-theobromin werden mit 600 ccm Methanol und 71, 5 g Cyclohexylamin im Autoklav 6 Stunden auf 130°C erhitzt. Man dampft die methanolische Lösung ein, 16st in Äthanol, säuert mit alkoholischer Salzsäure an, fällt mit Aceton. Es werden so 47 g 1- (#-Cyclohexylamino-äthyl)-theobromin-hydrochlorid vom Schmelzpunkt. 180 bis 183°C erhalten. Example 5 1- (ß-cyclohexylamino-ethyl) -theolbromine hydrochloride 41, 5 g of l-ß-chloroethyl-theobromine are mixed with 600 cc of methanol and 71.5 g of cyclohexylamine heated to 130 ° C. in the autoclave for 6 hours. The methanolic is evaporated Solution one, 16th in ethanol, acidified with alcoholic hydrochloric acid, precipitated with acetone. It will so 47 g of 1- (# -cyclohexylamino-ethyl) -theobromine hydrochloride of the melting point. 180 to 183 ° C obtained.

Beispiel 6 l- (-BenzyIamino-äthyl)-theobromin-hydrochlorid 27 g 1-ß-Chloräthyl-theobromin werden mit 41,2 g Benzylamin und 20 ccm Äthanol 8 Stunden unter Rückfluß erhitzt. Man engt die Lösung ein, säuert mit alkoholischer Salzsäure an und läßt das 1- (fl-Benzylaminoäthyl)-theobromin-hydrochlorid auskristallisieren. Nach dem Umkristallisieren aus Athanol beträgt der Schmelzpunkt 224 bis 226° C. Ausbeute 18 g. Example 6 l- (-BenzyIamino-ethyl) -theobromine hydrochloride 27 g of 1-ß-chloroethyl-theobromine are refluxed for 8 hours with 41.2 g of benzylamine and 20 ccm of ethanol. The solution is concentrated, acidified with alcoholic hydrochloric acid and the 1- (fl-benzylaminoethyl) -theobromine hydrochloride is left crystallize. After recrystallization from ethanol, the melting point is 224 to 226 ° C. Yield 18 g.

Claims (1)

PATENTANSPRUCH : Verfahren zur Herstellung von basisch substituierten Alkylxanthinderivaten oder deren Salzen durch Umsetzung von Halogenalkylxanthinen mit primären Aminen nach Patentanmeldung C 13726 IVb/12p, dadurch gekennzeichnet, daß man hier 1-Halogenalkyl-3,7-dimethylxanthine mit primären Alkyl-, Cycloalkyl-bzw. Aralkylaminen, zweckmäßig in Gegenwart von Lösungsmitteln, gegebenenfalls in einem geschlossenen Gefäß, bei höheren Temperaturen, vorzugsweise zwischen 110 und 170° C umsetzt. PATENT CLAIM: Process for the production of basic substituted Alkylxanthine derivatives or their salts by reacting haloalkylxanthines with primary amines according to patent application C 13726 IVb / 12p, characterized in that that here 1-haloalkyl-3,7-dimethylxanthines with primary alkyl, cycloalkyl or. Aralkylamines, expediently in the presence of solvents, optionally in one closed vessel, at higher temperatures, preferably between 110 and 170 ° C implements. In Betracht gezogene Druckschriften : Deutsche Patentschrift Nr. 870 109. Publications considered: German Patent No. 870 109.
DEC15043A 1956-09-25 1956-10-22 Process for the preparation of basic substituted alkylxanthine derivatives Pending DE1100641B (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DEC13727A DE1100640B (en) 1956-09-25 1956-09-25 Process for the preparation of basic substituted alkylxanthine derivatives
DEC13726A DE1095285B (en) 1956-09-25 1956-09-25 Process for the preparation of basic substituted alkylxanthine derivatives
DEC15043A DE1100641B (en) 1956-09-25 1956-10-22 Process for the preparation of basic substituted alkylxanthine derivatives

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DEC13726A DE1095285B (en) 1956-09-25 1956-09-25 Process for the preparation of basic substituted alkylxanthine derivatives
DEC15043A DE1100641B (en) 1956-09-25 1956-10-22 Process for the preparation of basic substituted alkylxanthine derivatives
DEC15044A DE1100642B (en) 1956-09-25 1957-06-22 Process for the preparation of basic substituted alkylxanthine derivatives

Publications (1)

Publication Number Publication Date
DE1100641B true DE1100641B (en) 1961-03-02

Family

ID=33101671

Family Applications (1)

Application Number Title Priority Date Filing Date
DEC15043A Pending DE1100641B (en) 1956-09-25 1956-10-22 Process for the preparation of basic substituted alkylxanthine derivatives

Country Status (1)

Country Link
DE (1) DE1100641B (en)

Similar Documents

Publication Publication Date Title
DE1695186B2 (en) 2-NITRO-1-IMIDAZOLYL ACID BENZYLAMIDE
DE1180372B (en) Process for the preparation of 2,6-dioxopiperazines
DE2429935C3 (en) Process for the preparation of 2,2,6,6-tetramethyl-4-oxopiperidine
CH380746A (en) Process for the preparation of new secondary amines
DE1100641B (en) Process for the preparation of basic substituted alkylxanthine derivatives
DE1212984B (en) Process for the production of basic substituted coumarones
DE2207098A1 (en) PROCESS FOR THE PRODUCTION OF 2,5-DIMETHYL-FURAN-3-CARBON ACID ESTERS
CH417630A (en) Process for the preparation of new cyclic 2,3-O-acetals and 2,3-O-ketals of butanetetrol esters
DE2218647A1 (en) Secretolytic n-(trans-4-hydroxycyclohexyl)-2-amino-3,5- - dibromobenzylamine prepn - by redn of n-(2-amino-3,5-dibromobenzylide
DE1011424B (en) Process for the preparation of basic substituted 7-alkyl-xanthine derivatives or their salts
DE1793693B2 (en)
AT210422B (en) Process for the preparation of new tertiary amines
DE2917178C2 (en)
DE1287584B (en) Process for the preparation of 2, 3-dihydro-1, 4-benzoxazine derivatives
EP0034746B1 (en) 5-sulfamoyl-orthanilic acids, processes for their preparation, therapeutic compositions containing them and the compounds for use in therapy
DE2509481C3 (en) Process for the preparation of N-acetylsalicylamide
AT203495B (en) Process for the preparation of new tertiary amines
AT303025B (en) PROCESS FOR THE PRODUCTION OF NEW INDOLDER DERIVATIVES AND THEIR ACID ADDITION SALTS
DE910648C (en) Process for the production of new azomethine compounds of phthalaldehydes
DE2019570C2 (en) Water-soluble khellin derivative: 1H, 3H-2-aza-4-methylene-5,8-dimethoxy-furo (2 ", 3", 6,7) xanthone-2-spiro-1'-piperidinium chloride and process for its preparation
DE1670907C3 (en) N-disubstituted 3-Am! No-1,2benzisothiazoles and process for their preparation
AT205037B (en) Process for the preparation of a new thioxanthene derivative
DE1643621C3 (en)
DE1285473B (en) Diastereomers of 1- (3'-thienylallyl) -3-methyl-4-phenyl-4-carbaethoxypiperidine and their acid addition salts
AT234691B (en) Process for the preparation of new piperidine derivatives